Phase I study of paclitaxel and etoposide for metastatic or recurrent malignancies

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 2, 1998, Pages 129-134

  Lilenbaum, Rogerio C ^a,d   MacManus, Dan ^b   Engstrom, Christine ^c   Green, Mark ^b  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BALTIMORE VA MEDICAL CENTER   (United States)

^d Miami Beach FL   (United States)

Author keywords

Etoposide; Paclitaxel; Phase I

Indexed keywords

ANTINEOPLASTIC AGENT; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; ETOPOSIDE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG INDUCED DISEASE; FEMALE; GERM CELL TUMOR; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MALE; METASTASIS; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; RECURRENT CANCER; SOLID TUMOR; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; FILGRASTIM; GERMINOMA; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL;

EID: 0031900377     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199804000-00006     Document Type: Article

References (17)

1. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995;332:1004-14.
2. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
3. Bonomi P, Kim K, Chang A, et al. Phase III trial comparing etoposide (E) cisplatin (C) versus taxol (T) with cisplatin-G-CSF (G) versus taxol-cisplatin in advanced non-small cell lung cancer (NSCLC) [Abstract 1145]. Proceedings of the American Society of Clinical Oncology 1996;15:382.
4. Rowinsky EK, Donehower RC. Vinca alkaloids and epipodophyllotoxins. In: Perry MC, ed. The chemotherapy source book. Baltimore: Williams & Wilkins, 1992:359-83.
5. Perez EA, Hack F, Fletcher T, et al. Sequence dependent cytotoxicity of taxol (tax) and etoposide (eto) in lung and breast human cancer cell lines [Abstract 1604]. Proceedings of the American Sociery of Clinical Oncology 1995;14:491.
6. Schiller JH, Storer B, Tutsch K, et al. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 1994;12:241-8.
7. Lilenbaum RC, Ratain MJ, Miller AA, et al. Phase I study of paclitaxel and topotecan in patients with advanced tumors: a Cancer and Leukemia Group B study. J Clin Oncol 1995;13:2230-7.
8. Vennok AP, Egorin M, Brown TD, et al. Paclitaxel (taxol) in patients with liver dysfunction (CALGB 9264) [Abstract 350]. Proceedings of the American Society of Clinical Oncology 1994;13:139.
9. Pestalozzi BC, Sotos GA, Choyke PL, et al. Typhlitis resulting from treatment with taxol and doxorubicin in patients with metastatic breast cancer. Cancer 1993;71:1797-1800.
10. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990;8:1263-8.
11. O'Dwyer P, Weus R. Hypersensitivity reactions induced by etoposide. Cancer Treat Rep 1984;68:959.
12. Schweitzer VG, Juillard GF, Bajada CL, et al. Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel. Cancer 1995;76:1069-72.
13. Ramanathan RK, Reddy VV, Holbert JM, et al. Pulmonary infiltrates following administration of paclitaxel. Chest 1996;110:289-92.
14. Murphy WK, Winn RJ, Huber M, et al. Phase II study of taxol in patients with non-small cell lung cancer who have failed platinum containing chemotherapy [Abstract 1224]. Proceedings of the American Society of Clinical Oncology 1994;13:363.
15. Hainsworth JD, Thompson DA, Greco FA. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small cell lung cancer. J Clin Oncol 1995;13:1609-14.
16. Ettinger DS, Finkelstein DM, Sarma R, et al. Phase II study of taxol in patients with extensive-disease small cell lung cancer [Abstract 1094]. Proceedings of the American Society of Clinical Oncology 1993;12:329.
17. Motzer RJ, Bajorin DF, Schwartz LH, et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 1994;12:2227-83.